2019
DOI: 10.1016/j.eururo.2019.01.031
|View full text |Cite
|
Sign up to set email alerts
|

Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
17
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 26 publications
(17 citation statements)
references
References 3 publications
(2 reference statements)
0
17
0
Order By: Relevance
“…More specifically, we will run focus groups with patients with BC and their families, healthcare professionals, physiotherapists and behavioural scientist to help identify whether the results of the scoping review truly reflect the needs and expectations of all stakeholders involved. We will invite and recruit participants for this consultation phase through our ongoing collaborations with patient advocacy organisations and healthcare professional organisations (eg, Action Bladder Cancer UK, Fight Bladder Cancer, British Association of Urological Surgeons, British Uro-Oncology Group) 21…”
Section: Protocol Designmentioning
confidence: 99%
“…More specifically, we will run focus groups with patients with BC and their families, healthcare professionals, physiotherapists and behavioural scientist to help identify whether the results of the scoping review truly reflect the needs and expectations of all stakeholders involved. We will invite and recruit participants for this consultation phase through our ongoing collaborations with patient advocacy organisations and healthcare professional organisations (eg, Action Bladder Cancer UK, Fight Bladder Cancer, British Association of Urological Surgeons, British Uro-Oncology Group) 21…”
Section: Protocol Designmentioning
confidence: 99%
“…However, previous studies have demonstrated both increased and decreased survival associated with delay to RC. The impact of this delay on survival outcomes has recently been identified as one of the top ten unanswered research questions by BC patients and health care professionals thus highlighting the importance of studying this topic (8).…”
Section: Introductionmentioning
confidence: 99%
“…Genomic and epigenomic approaches may thus inform the development of more accurate risk stratifiers and non-invasive diagnostics (19), tools that are urgently required by healthcare professionals and patients alike (20). CircRNAs also appear to have a role to play in this already complex setting as a novel class of prognostic biomarkers for NMIBC-in a pioneering study, Okholm et al (21) evaluated circRNAs in a large cohort (n = 457) of NMIBCs and identified circRNAs that are differently expressed between high and low risk tumors, highlighting two (circHIPK3 and circCDYL) as potential biomarkers (21).…”
Section: Introductionmentioning
confidence: 99%